









Markets
/
Stocks
/
nasdaq-cingw
/

Cingulate Inc

CINGW

View Detailed Chart

0.100USD

-0.019-16.52%

Close 08/01, 16:00（ET）Quotes delayed by 15 min

0.00Market Cap

--P/E TTM



Cingulate Inc

0.100

-0.019-16.52%

Overview Company Financials

Financials

Intraday

30m

Today

-16.52%

5 Days

-25.93%

1 Month

+124.72%

6 Months

+78.57%

Year to Date

+94.17%

1 Year

+1011.11%

View Detailed Chart

Agency Rating

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Neutral

Sell(4)

Neutral(3)

Buy(5)

Indicators

Sell(2)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.001

Neutral

RSI(14)

51.796

Neutral

STOCH(KDJ)(9,3,3)

29.513

Sell

ATR(14)

0.034

High Vlolatility

CCI(14)

-5.725

Neutral

Williams %R

55.597

Sell

TRIX(12,20)

4.795

Buy

StochRSI(14)

0.000

Oversold

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

0.116

Sell

MA10

0.136

Sell

MA20

0.091

Buy

MA50

0.066

Buy

MA100

0.052

Buy

MA200

0.051

Buy

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.

Ticker SymbolCINGW

CompanyCingulate Inc

CEODr. Shane J. Schaffer, Pharm.D.

Websitehttps://www.cingulate.com/